Lack of pharmacokinetic interaction between anidulafungin and tacrolimus

Journal of Clinical Pharmacology

Volumn 47, Issue 3, 2007, Pages 305-314

  Dowell, James A ^a,b   Stogniew, Martin ^a,c   Krause, David ^a,d   Henkel, Timothy ^a,e   Damle, Bharat ^a  

^a PFIZER INC   (United States)

^b SHIRE   (United States)

^c Zelos Therapeutics Inc   (United States)

^d Delta Pharmaceutical Consulting LLC

^e Ception Therapeutics   (United States)

Author keywords

Anidulafungin; Drug interaction; Pharmacokinetics; Tacrolimus; Tolerability

Indexed keywords

ANIDULAFUNGIN; TACROLIMUS;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; GRAFT RECIPIENT; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; NOCTURIA; NORMAL HUMAN; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; CREATINE KINASE; DIZZINESS; DRUG INTERACTIONS; FATIGUE; HALF-LIFE; HEADACHE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NOCTURIA; PEPTIDES, CYCLIC; TACROLIMUS; THERAPEUTIC EQUIVALENCY; THROMBOPHLEBITIS;

EID: 33847134856     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006296764     Document Type: Article

References (29)

1. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0091 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998 ; 36: 2950-2956.
2. Denning DW. Echinocandins and pneumocandins: a new anti-fungal class with a novel mode of action. J Microb Chemother. 1997 ; 40: 611-614.
3. Denning DW. Echinocandin antifungal drugs. Lancet. 2003 ; 362: 1142-1151.
4. Thye D, Shepherd B, White RJ, Weston IE, Henkel T. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers [poster 36]. Poster presented at: 41st Annual ICAAC Conference ; Chicago ; December 2001.
5. Brown GL, White RJ, Taubel J. Phase 1 dose optimization study for V-echinocandin [poster 1105]. Poster presented at: 40th Annual ICAAC Conference ; Toronto ; September 2000.
6. Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotrans-formation in humans by degradation not metabolism. Clin Microbiology Infec. 2003 ; 9: 291-291.
7. Dowell JA, Stogniew M, Krause D, Henkel T. Anidulafungin pharmacokinetic/pharmacodynamic correlation: treatment of EC [abstract A-1578]. Poster presented at: 43rd Annual ICAAC Conference ; Chicago ; September 2003.
8. Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004 ; 44: 590-598.
9. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995 ; 29: 404-430.
10. Sattler M, Guengerich FP, Yun C-H, Christians U, Sweing KF. Cytochrome P-450A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992 ; 20: 753-761.
11. Physicians Desk Reference. 58th ed. Montvale, NJ: Thompson PDR ; 2004.
12. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002 ; 41: 813-851.
13. Van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002 ; 25: 707-712.
14. FDA advisory meeting for Cancidas (caspofungin acetate), January 10, 2001.
15. Herbert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2005 ; 45: 1018-1024.
16. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005 ; 45: 227-233.
17. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002 ; 72: 660-669.
18. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006 ; 112: 184-198.
19. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis. 2004 ; 23: 805-812.
20. Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel anti-fungal agent caspofungin. Drug Metab Dispos. 2005 ; 33: 676-682.
21. Stone J, Holland S, Wickersham P, et al. Drug interactions between caspofungin and tacrolimus [poster A13]. Poster presented at: ICAAC ; Chicago ; December 16-19, 2001.
22. Caspofungin package insert. Whitehouse Station, NJ: Merck & Co.; 2003.
23. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin. 2003 ; 19: 263-271.
24. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis. 2002 ; 4: 25-30.
25. Cancidas (caspofungin acetate), Scientific Discussion, European Public Assessment Report, the European Agency for the Evaluation of Medicinal Products, October 2001. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/ cancidas/cancidas.htm. Accessed October 2, 2006.
26. Mycamine™ (micafungin sodium) for injection - US prescribing information. Astellas Pharma US Inc; April 2005.
27. Herbert MF, Townsend RW, Blough DK, Bekersky I. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2005 ; 45: 954-960.
28. Dowell JA, Pu F, Lee J, Stogniew M, Krause D, Henkel T. A clinical mass balance study of anidulafungin showing complete fecal elimination [poster A1576]. Poster presented at: ICAAC ; Chicago ; September 14-17, 2003.
29. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004 ; 39: 770-775.